Descrizione del progetto
Affrontare le disparità negli studi clinici in Africa
L’Africa, nonostante sia portatrice di oltre il 25 % del carico di malattia globale, a causa di vari fattori come la mancanza di competenze, normative poco chiare e dati inadeguati, attualmente conduce solo il 3 % delle sperimentazioni cliniche. Per affrontare questa disparità, il progetto CTCAN, finanziato dall’UE, istituirà la Clinical Trials Community Africa Network (CTCAN). L’obiettivo è promuovere la collaborazione tra le principali parti interessate della ricerca clinica, i partner farmaceutici e altre controparti internazionali nella regione africana. Lo scopo principale del progetto è migliorare il coordinamento e la sostenibilità della ricerca clinica attraverso l’allineamento della rete, la sensibilizzazione sulle strutture disponibili, l’ottimizzazione dei processi normativi e la promozione della condivisione delle conoscenze tra le regioni. La CTCAN fungerà da piattaforma preziosa che consolida le informazioni necessarie per migliorare la preparazione alle pandemie e sostenere gli sforzi di ricerca clinica.
Obiettivo
With over 25% of the global disease burden, only 3% of global clinical trials occur in Africa. This disproportion is driven by inadequacies in clinical research capacity, regulatory process ambiguity, deficient regional patient and disease area data, and lack of visibility of existing clinical research capabilities in Africa. To address this disproportion, this proposal seeks to establish the Clinical Trials Community Africa Network (CTCAN), a collaborative framework of key clinical research stakeholders in the African region, pharma partners, and other relevant international stakeholders, with the overarching goal of bringing more clinical trials to the region in a sustainable and coordinated manner. This collaboration will map and draw on the experience and expertise of already existing networks and initiatives. It will create a network of subnetworks that will foster coordination in clinical research, by ensuring and encouraging alignment in disease area prioritization, raising awareness and visibility of existing capacity from sites and labs across Africa, operationalising the regulatory processes across the region, and strengthen less experienced sites and labs through a clinical trial preparedness framework, while encouraging inter- and cross-continental knowledge and expertise sharing. CTCAN will use and expand the Clinical Trials Community (CTC) platform, an electronic platform consolidating data on researchers, regulations, sites, and epidemiology across the continent. The result will be an ever-present and ready-to-go pool of clinical research sites and labs with the agility to rapidly address new and emerging global health threats, epidemics, and pandemics, thereby efficiently contributing towards clinical research in pandemic preparedness. CTCAN will lay the foundation for a sustainable network of clinical trial sites and laboratories in sub-Saharan Africa by leveraging and initiating collaboration between existing sub-networks, funders, and pharma.
Parole chiave
Programma(i)
- HORIZON.2.1 - Health Main Programme
Meccanismo di finanziamento
HORIZON-JU-CSA - HORIZON JU Coordination and Support ActionsCoordinatore
2007 JOHANNESBURG
Sud Africa